Figure S1. Diagnostic algorithm starting with holoTC as a first line markers then MMA as a second line marker.

Figure S2. The correlation between serum MMA and holoTC according to serum creatinine.

Figure S3. Number of cases with holoTC in the gray range according to concentrations of MMA and serum creatinine.

Figure S4. The correlation between the reduction in MMA and baseline holoTC in renal patients (the majority of them had severely elevated MMA) treated with vitamin B12 over 1 month.

eci12034-sup-0002-Legend.docWord document21K 

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.